ATTBF - Abattis Bioceuticals Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.086475
-0.009825 (-10.20%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.096300
Open0.098000
Bid0.000000 x 0
Ask0.000000 x 0
Day's Range0.085000 - 0.098000
52 Week Range0.074900 - 0.744400
Volume506,109
Avg. Volume1,145,593
Market Cap36.783M
Beta (3Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-0.078000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Abattis Bioceuticals Offers Comfort to Those Suffering with Chronic Pain & Inflammation -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering the launch of Abattis Bioceuticals Corp.'s (ATT.CN) (ATTBF) latest product innovation. “Comfort”, a nutraceutical designed to alleviate chronic pain and inflammation, is the first in line of a dozen new products the company expects to launch over 36 months. According to a recent Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, stated, “Acute or chronic pain is a significant public health problem that costs society at least $560-$635 billion annually in North America alone.

  • Newsfile25 days ago

    Abattis Bioceuticals Announces Board Change

    Vancouver, British Columbia--(Newsfile Corp. - October 19, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") is pleased to announce the additions of Kent McParland and Cedric Wilson to the Board of Directors (the "Board"). Mr. McParland and Mr. Wilson replace Cameron Paddock and Rene David who have left Abattis to concentrate on other ventures. Mr. McParland is a Chartered Professional Accountant experienced in multiple industries and geographical locations. ...

  • GlobeNewswire27 days ago

    Abattis Bioceuticals Celebrates Legalization

    Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to celebrate the legalization of cannabis in Canada. This is a truly a newsworthy day in Canadian history, as we formally recognize the end of cannabis prohibition in our country. As Ottawa subsequently, decreed Legalization on Oct.17th, 2018 - Canada is now the second country in the world, and first G7 nation to legalize marijuana production, sale and consumption country-wide.

  • GlobeNewswirelast month

    Abattis Bioceuticals Provides Update on Vaporizer Product Line

    Abattis Bioceuticals Corp. (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce an update on our recent product line addition of three new vaporizers. The “VB-2” uses a compact 350mAh variable voltage battery, designed with built-in protections against short-circuiting and overheating, and features a conventional preheating function that the user activates with two clicks of a button. The cutting-edge device is equipped with a 510-threaded connection that can be closed to house attachments and features a built-in USB charging cable, a long-lasting embedded 350mAh lithium ion battery, a key ring and an LED light indicator.

  • GlobeNewswirelast month

    Abattis Bioceuticals Provides Phase 1 Update on Research and Development for Nanoemulsification and Liposomal Platforms of Cannabinoid-Rich Hemp Oil

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT) (OTC: ATTBF) is pleased to announce that the research being done in conjunction with the University of British Columbia and Mitacs is close to completing their phase of testing. In Q1 2018, Abattis announced a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil. The research and development work has been led by scientists from Abattis and the Faculty of Land and Food Systems at the University of British Columbia ("UBC").

  • GlobeNewswire2 months ago

    Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the Company hopes to launch Comfort on Cyber Monday through the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. “According to a report from the Industry of Medicine, more than 100 million people in North America suffer from chronic pain and inflammation1,” stated Rob Abenante, Abattis President and CEO.  “That same report estimates the pain-price tag for medical treatments and lost productivity at more than $600 billion annually1, making chronic pain and inflammation major drains on the economy.

  • GlobeNewswire2 months ago

    Abattis Strengthens Management Team and Provides Company Updates

    Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide the following corporate updates. The Company is pleased to announce the appointment of Nicole Breitinger as the Company’s corporate secretary. Ms. Breitinger brings considerable experience to her role, having spent more than twenty years providing corporate services to companies across a range of industries.

  • GlobeNewswire3 months ago

    Abattis Prepares to Launch New Products Through Vergence Naturals

    Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce that it plans to launch a new line of products designed to alleviate pain and inflammation through its wholly owned subsidiary, Vergence Naturals Ltd. (“Vergence”). The launch is anticipated to take place on Cyber Monday and the new product line will be the first of twelve products the Company hopes to launch over a 36-month period. “We are very proud to have developed two products that safely reduce pain and modulate inflammation.

  • CNW Group5 months ago

    Abattis and BLOCKStrain Execute Letter of Intent for Product Integration and Strategic Partnership

    OTC:ATTBF) ("Abattis") and BLOCKSTRAIN TECHNOLOGY CORP. ("BLOCKStrain") (TSXV: DNAX.V) are pleased to announce that they have signed a letter of intent (the "LOI") to integrate BLOCKStrain's proprietary technology into Abattis's  product and services ecosystem. Through their collaboration, the parties hope to enable Abattis clients to instantly arrange for sales, shipping, testing and analysis of Abattis products and give clients comprehensive visibility over such products over their entire lifecycles. Abattis and BLOCKStrain also intend to explore development and integration opportunities to expand on Abattis's current life sciences and biotechnology services offerings.